AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30927415 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa trigger (buserelin 0.5 mg)
Number of subjects: 384
Study 29467392 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage (PostBev)
Number of subjects: 15
Study 29467392 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (PostBev)
Number of subjects: 15
Study 26742509 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) - 78‐234 mg, monthly injectable
Number of subjects: 444
Study 26742509 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotics (OA) - daily treatment
Number of subjects: 444
Study 23795823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐Family Psychoeducational Psychotherapy (MF‐PEP)
Number of subjects: 165
Study 23795823 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 165
Study 22443173 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (250 mg per day)
Number of subjects: 0
Study 22443173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20226144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Granule (BSHXG)
Number of subjects: 120
Study 20226144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17919541 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir 10 mg once daily for 28 days
Number of subjects: 3363
Study 17919541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3363
Study 16208616 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 112
Study 16208616 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart valve surgery
Number of subjects: 112
Study 16208616 — intervention group
Group type: COMPARATOR
Intervention: Preoperative evaluation
Number of subjects: 112
Study 11872977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led education and support
Number of subjects: 20
Study 11872977 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient education by physician
Number of subjects: 20
Study 10915082 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day oral antibiotics
Number of subjects: 4782
Study 10915082 — intervention group
Group type: COMPARATOR
Intervention: 10-day penicillin V
Number of subjects: 4782
Study 8955760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg/day (group A)
Number of subjects: 189
Study 8955760 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 189
Study 4000532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiropramide hydrochloride 100 mg t.i.d. for 4 weeks
Number of subjects: 40
Study 4000532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31056840 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg danirixin hydrobromide
Number of subjects: 34
Study 31056840 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg danirixin hydrobromide
Number of subjects: 34
Study 31056840 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg danirixin hydrobromide
Number of subjects: 34
Study 31056840 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg danirixin hydrobromide (fed state - low-fat meal)
Number of subjects: 34
Study 31056840 — intervention group
Group type: COMPARATOR
Intervention: Control (fasted state)
Number of subjects: 34
Study 31056840 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety profile of danirixin
Number of subjects: 34
Study 29596127 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative feeding
Number of subjects: 92
Study 29596127 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 92
Study 27816118 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-MB elevation in the first 24 hours after CABG
Number of subjects: 0
Study 27816118 — intervention group
Group type: EXPERIMENTAL
Intervention: New Q waves post-CABG
Number of subjects: 0
Study 27816118 — intervention group
Group type: EXPERIMENTAL
Intervention: New Q waves (when CK-MB is excluded)
Number of subjects: 0
Study 25114912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation for 4 weeks
Number of subjects: 0
Study 25114912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23528001 — intervention group
Group type: EXPERIMENTAL
Intervention: Search display interrupted with a blank screen during visual search tasks.
Number of subjects: 0
Study 23528001 — intervention group
Group type: EXPERIMENTAL
Intervention: Half the distractors were blue and half were yellow in Experiment 2.
Number of subjects: 0
Study 19478822 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (macular relocation)
Number of subjects: 28
Study 19478822 — intervention group
Group type: COMPARATOR
Intervention: Control (observation or photodynamic therapy)
Number of subjects: 28
Study 17963760 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulfate tablet containing 50 mg elemental iron daily)
Number of subjects: 66
Study 17963760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 66
Study 16816276 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention including psychoeducation, simplified practice guidelines, and nurse care coordinator support
Number of subjects: 0
Study 16816276 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14641799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) once daily for five consecutive days
Number of subjects: 441
Study 14641799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 10985708 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 1159
Study 10985708 — intervention group
Group type: COMPARATOR
Intervention: No angiography
Number of subjects: 1159
Study 8774094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 9310
Study 1593553 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vaginal suppositories of 10 mg of prostaglandin E2 (17 patients)
Number of subjects: 50
Study 1593553 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intravesical solution of 50 micrograms of prostaglandin F2 alpha dissolved in 100 mL of normal saline (15 patients)
Number of subjects: 50
Study 1593553 — intervention group
Group type: COMPARATOR
Intervention: Daily instillation of 100 mL of saline (18 patients)
Number of subjects: 50
Study 1593553 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 50
Study 31833064 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure management (130-150 mmHg)
Number of subjects: 51
Study 31833064 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented systolic blood pressure management (160-180 mmHg)
Number of subjects: 51
Study 31833064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 31062541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (two sessions per week, four 4-minute intervals at 85-95% HRmax with 3-minute active breaks at 70% HRmax)
Number of subjects: 12
Study 31062541 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 12
Study 27992112 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (25 IU kg-1 body weight two times per week for 10 weeks, then 30-40 IU kg-1 two times per week or randomized to every-5-days (45-60 IU kg-1) or every-7-days (60 IU kg-1) prophylaxis for 26 weeks)
Number of subjects: 132
Study 27992112 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (every-5-days treatment)
Number of subjects: 132
Study 27992112 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027 (every-7-days prophylaxis)
Number of subjects: 132
Study 27992112 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 94-9027
Number of subjects: 132
Study 25530148 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment participants (SPs)
Number of subjects: 58
Study 25530148 — intervention group
Group type: COMPARATOR
Intervention: Control participants (SPs)
Number of subjects: 58
Study 23387374 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment 1
Number of subjects: 71
Study 23387374 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment 2
Number of subjects: 71
Study 23387374 — intervention group
Group type: COMPARATOR
Intervention: vehicle 1
Number of subjects: 71
Study 23387374 — intervention group
Group type: COMPARATOR
Intervention: vehicle 2
Number of subjects: 71
Study 21429214 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC/IL‐2 treatment
Number of subjects: 320
Study 21429214 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 320
Study 19320915 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based oral health programme (OHP) targeting MS-positive subjects, involving repeated health education for caretakers and xylitol lozenges for children.
Number of subjects: 794
Study 19320915 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral health programme (control group).
Number of subjects: 794
Study 18081669 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster evaluation group
Number of subjects: 277
Study 18081669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booster evaluation)
Number of subjects: 277
Study 15712727 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 9
Study 15712727 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DUS
Number of subjects: 9
Study 11240075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg bid
Number of subjects: 60
Study 11240075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg bid
Number of subjects: 60
Study 11240075 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs alone
Number of subjects: 60
Study 9874916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild head injury (HI)
Number of subjects: 339
Study 9874916 — intervention group
Group type: EXPERIMENTAL
Intervention: Other injuries
Number of subjects: 339
Study 9874916 — intervention group
Group type: COMPARATOR
Intervention: No injury (NI)
Number of subjects: 339
Study 8033491 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 250 mg every morning for 10 days
Number of subjects: 0
Study 8033491 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 50 mg every morning for 10 days
Number of subjects: 0
Study 8033491 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 125 mg every morning for 10 days
Number of subjects: 0
Study 8033491 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 250 mg every 12 hours for 10 days
Number of subjects: 0
Study 8033491 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0591 (all doses)
Number of subjects: 0
Study 2567113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (200 to 1,600 mg once daily)
Number of subjects: 449
Study 2567113 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 to 400 mg once daily)
Number of subjects: 449
Study 30789583 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (3 sets of 30 seconds)
Number of subjects: 45
Study 30789583 — intervention group
Group type: COMPARATOR
Intervention: No stretching (control)
Number of subjects: 45
Study 30789583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching (3 sets of 30 repetitions)
Number of subjects: 45
Study 31148411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 459
Study 31148411 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 459
Study 31148411 — intervention group
Group type: EXPERIMENTAL
Intervention: PVS > -4% at baseline
Number of subjects: 459
Study 28976408 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 145
Study 26169561 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine
Number of subjects: 40
Study 26169561 — intervention group
Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 40
Study 23203241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin, starting at 150 mg/day, increasing to 300 or 450 mg/day
Number of subjects: 106
Study 23203241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 106
Study 21352267 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 0
Study 21352267 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 0
Study 21352267 — intervention group
Group type: COMPARATOR
Intervention: tolterodine ER 4 mg
Number of subjects: 0
Study 21352267 — intervention group
Group type: COMPARATOR
Intervention: tolterodine ER 8 mg
Number of subjects: 0
Study 21352267 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine
Number of subjects: 0
Study 21352267 — intervention group
Group type: COMPARATOR
Intervention: tolterodine ER
Number of subjects: 0
Study 19701575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 101
Study 19701575 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 101
Study 17897926 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 35
Study 17897926 — intervention group
Group type: COMPARATOR
Intervention: Control (no verapamil)
Number of subjects: 35
Study 15129933 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (3 x 10-g doses for 7 days)
Number of subjects: 20
Study 15129933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11284061 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0
Study 11284061 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 0
Study 11284061 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9134282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d.
Number of subjects: 95
Study 9134282 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 20 mg t.i.d.
Number of subjects: 95
Study 9134282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil
Number of subjects: 95
Study 9134282 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 95
Study 9134282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil and ISDN
Number of subjects: 95
Study 7946235 — intervention group
Group type: EXPERIMENTAL
Intervention: Community follow-up programme in psychiatric out-patient clinics
Number of subjects: 308
Study 7946235 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardianship networks operated by non-professional volunteers
Number of subjects: 308
Study 7946235 — intervention group
Group type: EXPERIMENTAL
Intervention: Work therapy stations
Number of subjects: 308
Study 7946235 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 308
Study 3284488 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CTZ) 480 mg three times a day for 24 weeks
Number of subjects: 13
Study 3284488 — intervention group
Group type: COMPARATOR
Intervention: Sulphapyridine 1.25 g a day
Number of subjects: 13
Study 28557858 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and sprint-training (CT)
Number of subjects: 25
Study 28557858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint-training (ST)
Number of subjects: 25
Study 27779312 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 36
Study 27779312 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 27779312 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent stimulation
Number of subjects: 36
Study 27779312 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation
Number of subjects: 36
Study 25768057 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral sequential endoscopic thoracic sympathectomy (S‐ETS)
Number of subjects: 407
Study 25768057 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous bilateral endoscopic thoracic sympathectomy (B‐ETS)
Number of subjects: 407
Study 23032404 — intervention group
Group type: COMPARATOR
Intervention: Brochure group (control)
Number of subjects: 205
Study 23032404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 205
Study 23032404 — intervention group
Group type: COMPARATOR
Intervention: Normal care group (control)
Number of subjects: 205
Study 21869698 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 427
Study 21869698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 19994560 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM‐SRP)
Number of subjects: 20
Study 19994560 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing (Q‐SRP)
Number of subjects: 20
Study 17179734 — intervention group
Group type: EXPERIMENTAL
Intervention: AST‐120 co‐administered with ongoing treatment
Number of subjects: 43
Study 17179734 — intervention group
Group type: COMPARATOR
Intervention: Ongoing treatments only (control group)
Number of subjects: 43
Study 16779302 — intervention group
Group type: EXPERIMENTAL
Intervention: Software architecture for simultaneous voice conferencing and remote device control over a single telephone line
Number of subjects: 0
Study 12411880 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic wax containing benzocaine
Number of subjects: 70
Study 12411880 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated orthodontic wax
Number of subjects: 70
Study 10222447 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole (40 mg)
Number of subjects: 16
Study 10222447 — intervention group
Group type: COMPARATOR
Intervention: omeprazole MUPS (20 mg)
Number of subjects: 16
Study 7838902 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (women with recent weight gain)
Number of subjects: 13
Study 7838902 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 13
Study 2331418 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine (10 micrograms) administered alone
Number of subjects: 76
Study 2331418 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine mixed with DTP vaccine
Number of subjects: 76
Study 2331418 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine administered alone
Number of subjects: 76
Study 395959 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐methyl‐N‐(beta‐hydroxyethyl) guanidine O‐phosphate (creatinol O‐phosphate, COP)
Number of subjects: 0
Study 395959 — intervention group
Group type: COMPARATOR
Intervention: Reference substance (solvent of COP)
Number of subjects: 0
Study 31360162 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Hz transcranial alternating current stimulation (tACS) applied to the dorsolateral prefrontal cortex (DLPFC) during Stroop task performance
Number of subjects: 0
Study 31360162 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 31360162 — intervention group
Group type: COMPARATOR
Intervention: 9.7 Hz tACS (nonharmonic alpha band control)
Number of subjects: 0
Study 27840069 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with the same first-line ACT
Number of subjects: 571
Study 27840069 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative ACT
Number of subjects: 571
Study 27840069 — intervention group
Group type: COMPARATOR
Intervention: Quinine-clindamycin (QnC)
Number of subjects: 571
Study 27840069 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with the same ACT
Number of subjects: 571
Study 24950276 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical nomograms based on sex, serum albumin, platelet count, microvascular invasion, and calculated tumor volume.
Number of subjects: 1085
Study 24950276 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical nomograms validated in an independent cohort.
Number of subjects: 1085
Study 24950276 — intervention group
Group type: COMPARATOR
Intervention: Statistical nomograms compared to conventional staging systems.
Number of subjects: 1085
Study 24074514 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cognitive screening battery
Number of subjects: 123
Study 24074514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental Status Examination (MMSE)
Number of subjects: 123
Study 21775749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 1791
Study 21775749 — intervention group
Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 1791
Study 19291496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) using the Modified Teaching Kids to Cope (MTKC)
Number of subjects: 84
Study 19291496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 84
Study 17091022 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Managers (MM)
Number of subjects: 928
Study 17091022 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Alarms (ALR)
Number of subjects: 928
Study 17091022 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 928
Study 15303639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3 microg/kg)
Number of subjects: 42
Study 15303639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15303639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 11739446 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg nateglinide
Number of subjects: 21
Study 11739446 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glyburide
Number of subjects: 21
Study 11739446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9432479 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms synthetic estrogen
Number of subjects: 0
Study 9432479 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms synthetic estrogen
Number of subjects: 0